Introduction
In recent years, the U.S. Senate has increasingly held hearings to grapple with one of the thorniest tensions in American drug policy: how (and whether) to fund rigorous scientific research into cannabis. On one hand, more than 30 states permit cannabis in some form; on the other, federal law still classifies cannabis as a Schedule I controlled substance, making research grants, clinical trials, and academic inquiry subject to heavy regulatory burdens. That contradiction has left scientists, patients, and policymakers frustrated—and Senate hearings have become a high-stakes stage for debating whether the federal government should unshackle itself from policies rooted in stigma rather than evidence.
In these hearings, senators invite leading scientists, medical professionals, drug enforcement officials, and patient advocates to testify about the barriers to research and to propose legislative or regulatory fixes. From the Compassionate Access, Research Expansion, and Respect States (CARERS) Act to the recent push for an Evidence-Based Drug Policy Act, Senate panels are probing how to recalibrate the balance between public health, drug control, and scientific freedom. These hearings not only shine a spotlight on structural constraints—DEA licensing delays, federal funding prohibitions, and scheduling mandates—but also help shape momentum for reforming federal cannabis research funding.
In this post, we’ll walk you through the key takeaways from recent Senate hearings, explore the institutional and legal barriers that persist, examine the reforms under consideration, and consider what might realistically change in the near term. Whether you’re a researcher, policy wonk, or cannabis-curious citizen, this deep dive will help you understand how Congress wrestles with turning cannabis from taboo to testable.
Key Takeaways
- Senate hearings have repeatedly spotlighted the tension between state legalization and federal prohibition, urging reform of funding, scheduling, and oversight structures.
- Bills such as the CARERS Act and the newer Evidence-Based Drug Policy Act aim to remove statutory restrictions and allow federal agencies to support cannabis research more directly.
- Despite vocal interest, political and procedural hurdles—especially scheduling, appropriations riders, and entrenched agency rules—still pose major obstacles.
- The 2022 Medical Marijuana and Cannabidiol Research Expansion Act made modest progress by easing researcher registration barriers (overview; news; trade coverage; university brief).
- Experts believe a combination of legislative reforms, agency rule changes, and presidential or administrative will could finally shift the research environment.
The Institutional Roadblocks to Cannabis Research
Even as states liberalize cannabis laws, the federal machinery remains hostile to large-scale scientific trials. Senate hearings frequently zero in on the institutional obstructions built into law and regulation.
DEA & NIDA Gatekeeping
One recurring theme in hearings is the bottleneck caused by DEA registration and NIDA’s historic control over cannabis supplies for research. Under current rules, researchers must obtain multiple licenses and navigate overlapping agencies to get permission to handle Schedule I cannabis. The National Institute on Drug Abuse’s role and supply pathways illustrate how access and manufacturer approvals function in practice. Peer-reviewed work has also documented the research barriers and methodological challenges in this space (open-access review). Senate testimonies have repeatedly pointed to years-long delays in those approvals as a deterrent to serious research.
Statutory Mandates That Block Funding
Some of the toughest constraints are not regulatory but statutory. One such statute from the Office of National Drug Control Policy (ONDCP) reauthorization era has been interpreted to push the agency toward opposing rescheduling efforts. Congressional analysts have long chronicled how ONDCP’s mandate and budget oversight shape federal drug policy implementation (see the nonpartisan CRS backgrounder on ONDCP authorities, RL32352).
Moreover, appropriations bills sometimes include riders that explicitly prohibit federal funds from being used to alter the scheduling of cannabis. For example, recent House action for FY26 included language to block rescheduling (industry report; policy newsletter). Related budget debates have also touched on hemp program restrictions (CRS In Focus IN12565), underscoring how appropriations can steer substance policy at the margins.
Fragmentation Among Agencies & Overlapping Oversight
Senators in hearings often lament how fragmented oversight across NIH, ONDCP, DEA, FDA, and NIDA leads to delays, miscommunication, and conflicting mandates. Even if NIH supports a cannabis-related grant, DEA licensing can block the actual procurement of cannabis materials, and the FDA may require additional safety or trial oversight. Hearing records capture these frictions in detail (see, e.g., a representative Senate/House hearing transcript: CHRG-116hhrg48043).
Landmark Legislative Efforts Spotlighted in Senate Hearings
In Senate hearings, congressional actors regularly present bills intended to fix the broken system. Below are some of the key legislative proposals that have featured in those discussions.
CARERS Act: Bipartisan but Limited
The Compassionate Access, Research Expansion, and Respect States (CARERS) Act has been a recurring subject in Senate debates. Sponsors have argued that it would allow states to set their own medical cannabis policies and remove regulatory hurdles that block research. However, critics note that while CARERS would remove some barriers, it doesn’t fully overhaul legacy statutory constraints—many of which are traced in policy histories like the Seton Hall analysis (Hudak/Wallack/Grossman 2019).
Medical Marijuana and Cannabidiol Research Expansion Act
A more concrete stride was made with the Medical Marijuana and Cannabidiol Research Expansion Act (MMCREA), passed in December 2022. That law creates a formal registration system for researchers, manufacturers, and distributors to legally engage with cannabis for research purposes and protects certain physician-patient discussions (CMCR overview; Pharmacy Times; Wikipedia summary; Rutgers brief). In Senate hearings, proponents hail this act as a foundational step that lowers some administrative burdens—yet it doesn’t resolve scheduling or appropriations constraints (bill text again for reference).
Evidence-Based Drug Policy Act (2025)
One of the more ambitious proposals currently discussed is the Evidence-Based Drug Policy Act of 2025. Among other reforms, it seeks to remove statutory impediments within the federal apparatus that have chilled research coordination and funding.
Cannabis Administration and Opportunity Act
Although broader in scope, the Cannabis Administration and Opportunity Act (CAOA) has also appeared in committee discussions. Supporters point to its comprehensive approach and the Senate Democrats’ official fact sheet as a roadmap, while legal researchers review specific sections in the bill text.
What Senate Hearings Reveal: Insights From Testimony
Beyond legislation, the actual testimonies in Senate hearings offer revealing glimpses into where the research and policy communities agree—and where they clash.
Voices from the Research Frontlines
In hearings convened across chambers, officials from NIH and leading medical researchers testified that the dearth of federal funding severely limits sample size, diversity of strains, and long-term studies. The repeated refrain: “we need access before we can answer the crucial questions.” Open hearing records (e.g., CHRG-116hhrg48043) and scholarly syntheses (methodological overview) echo these themes.
One Drug Caucus session highlighted parents of epileptic children who argued that CBD had life-changing effects, yet fear and legal risk make broader trials difficult—reinforcing the rationale behind MMCREA’s passage (MMCREA background; CMCR note).
Resistance from Enforcement & Regulatory Perspectives
Agency and law-enforcement witnesses often push back on sweeping reforms. DEA representatives have argued that existing regulations already allow for research flexibility and caution that rescheduling could weaken federal control; NIDA’s own supply framework is outlined here: NIDA’s Role in Providing Cannabis for Research.
Political Posturing vs. Practical Realities
Senators sometimes use hearings to signal priorities while the detailed back-and-forth focuses on narrow technical obstacles: licensing delays, grant review procedures, and conflicting mandates—well documented in hearing records (example transcript) and policy histories (Seton Hall policy analysis).
What Might Change—and What Probably Won’t (Yet)
Realistic Gains in the Short Term
- Targeted statutory fixes and rider reforms (see FY26 debates to block rescheduling: Cannabis Science & Tech; Marijuana Moment; hemp guardrails: CRS IN12565).
- Interagency coordination improvements grounded in existing authorities (context: ONDCP reauthorization background; CRS RL32352).
- More frequent agency-funded pilot studies and expanded research supply pathways (NIDA supply).
- Continued operationalization of 2022 reforms (MMCREA; Pharmacy Times).
Less Likely in the Near Term
- Full descheduling or wholesale federal legalization (debated in the CAOA and its fact sheet), absent broader political alignment.
- A massive, immediate surge of NIH-funded large-scale clinical trials before structural barriers are addressed.
- Rapid cultural change inside agencies despite statutory tweaks (see long-running tensions in policy analyses and hearing records).
Conclusion: Senate Hearings as a Crucible for Change
Senate hearings on cannabis research funding are not mere spectacles—they are strategic nodes where science, law, and politics collide. They provide a platform for advocates to humanize barriers, for agencies to explain constraints, and for Congress to test legislative fix proposals in public view. Over time, the cumulative pressure generated in committee rooms can shift ceilings of what policymakers believe is possible.
Still, hearings alone don’t drive reform. They must be followed by concrete legislative votes, rulemaking inside agencies, and sustained pressure to remove appropriations riders that thwart good proposals. For scientists eager to launch trials, the slow churn is not nearly fast enough. But each hearing’s transcript represents progress: the acknowledgment that cannabis research funding is not a fringe issue but a mainstream question of public health, federal policy, and American science. If we are entering a moment where ideology yields (at least in part) to evidence-based policy, Senate hearings are the crucibles wherein that transformation may be forged.
Frequently Asked Questions
Why does the Senate focus on cannabis research funding instead of outright legalization?
The Senate uses hearings to address the narrower, politically more viable question of how research can proceed within existing federal constraints. Legalization remains a broader, more polarized issue. Hearings build consensus on research reform, which may incrementally open the door to larger reforms (see comprehensive frameworks like the CAOA and its fact sheet).
Does passage of the 2022 research expansion act mean all cannabis research is now allowed?
Not quite. The Medical Marijuana and Cannabidiol Research Expansion Act eases registration and supplier obstacles, but it doesn’t eliminate major federal funding restrictions, scheduling constraints, or appropriations riders. For context and summaries: Wikipedia, CMCR, Pharmacy Times, Rutgers.
What is the Evidence-Based Drug Policy Act, and how does it relate to Senate hearings?
The Evidence-Based Drug Policy Act of 2025 is a proposed bill aimed at removing statutory impediments and improving interagency coordination for research. It often surfaces in hearings as a vehicle to normalize funding and streamline approvals.
Do Senate hearings guarantee policy change?
No. Hearings are advisory rather than binding. Real change requires legislation, appropriations, agency rulemaking, and enforcement. Recent budget activity illustrates how riders can stall change even amid momentum (FY26 rider to block rescheduling; newsletter recap). Broader legal frameworks like the CAOA (see text) remain under debate.
